Illumina CEO deSouza: Innovation Is ‘Our North Star’
Sequencing group sees a growing role for genomics in infectious disease
Executive Summary
The total addressable market for genomics-based infectious disease testing has expanded in recent months, says Illumina, after becoming the first company to receive a US EUA for a next-generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego company.
You may also be interested in...
Illumina Advances Precision Oncology And Gains Speed In Infectious Disease
Illumina’s moves into infectious disease testing and further into the clinical setting have been accelerated by the pandemic. The genomic sequencing company is also fast expanding its companion diagnostics oncology partnerships.
Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
First Test That Can Detect COVID-19 Virus Mutations Authorized By FDA
The US FDA on 10 June authorized use of Illumina’s COVIDSeq next generation sequencing diagnostic test to detect the SARS-CoV-2 virus and figure out if it’s mutating. The agency has high hopes this first-of-its-kind test will give researchers a better picture in the ongoing global fight against the COVID-19 pandemic.